Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Cerity Partners LLC

Cerity Partners LLC boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 29.9% during the 3rd quarter, Holdings Channel reports. The firm owned 790,636 shares of the company’s stock after acquiring an additional 181,933 shares during the quarter. Cerity Partners LLC’s holdings in Novo Nordisk A/S were worth $94,141,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in NVO. Nicolet Advisory Services LLC increased its holdings in shares of Novo Nordisk A/S by 10.7% during the 3rd quarter. Nicolet Advisory Services LLC now owns 3,351 shares of the company’s stock valued at $386,000 after purchasing an additional 323 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd acquired a new stake in shares of Novo Nordisk A/S in the third quarter worth approximately $714,000. Nwam LLC purchased a new stake in shares of Novo Nordisk A/S during the third quarter worth $330,000. Meridian Wealth Management LLC acquired a new stake in Novo Nordisk A/S in the 3rd quarter valued at about $15,108,000. Finally, GM Advisory Group LLC acquired a new stake in shares of Novo Nordisk A/S in the third quarter valued at approximately $337,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

NVO has been the topic of a number of recent analyst reports. BMO Capital Markets decreased their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $144.50.

Novo Nordisk A/S Stock Up 2.4 %

Shares of NYSE NVO opened at $105.07 on Friday. The stock has a market cap of $471.50 billion, a PE ratio of 34.00, a price-to-earnings-growth ratio of 1.32 and a beta of 0.42. Novo Nordisk A/S has a 52-week low of $94.73 and a 52-week high of $148.15. The business has a 50-day moving average price of $115.48 and a 200 day moving average price of $128.79. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.